From WikiProjectMed
Jump to navigation Jump to search
Clinical data
Drug classEnzyme[1]
Main usesMucopolysaccharidosis II (MPS-II)[1]
Side effectsRash, fever, headache, high blood pressure, flushing[2]
Typical dose0.5 mg/kg q 1 week[3]
External links
US NLMIdursulfase
License data
 ☒NcheckY (what is this?)  (verify)

Idursulfase, sold under the brand name Elaprase, is a medication used to treat mucopolysaccharidosis II (MPS-II, Hunter syndrome).[1] It is given by gradual injection into a vein.[1] It is used long term.[3] Effects on life expectancy and quality of life is unclear.[4]

Common side effects include rash, fever, headache, high blood pressure, and flushing.[2] Other side effects may include shortness of breath, heartburn, chest pain, and anaphylaxis.[2] It is a form of lysosomal enzyme known as iduronate-2-sulfatase and is made by recombinant DNA technology.[1]

Idursulfase was approved for medical use in the United States in 2006 and Europe in 2007.[1][2] In the United States it costs about 475,000 USD to treat a 35 kg person for a year.[5] In the United Kingdom this amount costs £310,000.[3]

Medical uses


It is given at a dose of 0.5 mg/kg once per week.[3]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Idursulfase Monograph for Professionals". Retrieved 25 November 2021.
  2. 2.0 2.1 2.2 2.3 "Elaprase". Retrieved 25 November 2021.
  3. 3.0 3.1 3.2 3.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1116. ISBN 978-0857114105.
  4. "Idursulfase" (PDF). September 2009. Retrieved 25 November 2021.
  5. "Idursulfase Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 25 November 2021.

External links